Alcon agreed to buy Neurotech Pharmaceuticals for $550 million upfront, aiming to broaden its ophthalmic portfolio with an FDA-approved asset. The acquisition adds a new development pipeline under Alcon’s eye-focused growth strategy and positions the company to advance late-stage programs and potential lifecycle expansions. The transaction reflects continued consolidation in eye care, where device and drug modalities increasingly overlap and commercial execution depends on integrated clinical evidence and regulatory continuity. With additional milestone payments possible, the deal structure keeps upside tied to execution. For partners, Neurotech’s platform and clinical assets now shift into Alcon’s resource base, with implications for timelines, trial design, and next-generation product prioritization.